Nov 04, 2013 8:51am EST OPKO Commences Pivotal Clinical Validation Study for 4Kscore™ as a Predictor of Prostate Cancer Prior to Biopsy
Oct 10, 2013 9:00am EDT OPKO Adds to Growing Technology Portfolio Through Strategic Investment in Biotechnology Company Engaged in the Development of a New Generation of Antibodies
Jul 16, 2013 9:17am EDT OPKO Health Announces Appointment of David Okrongly, Ph.D. as President of its Diagnostics Business Unit